Hypothyroidism and dyslipidemia: Modern concepts and approaches

被引：91

作者：

Pearce E.N. ^{[1
]}

机构：

[1] Boston University Medical Center, Boston, MA 02118

来源：

Current Cardiology Reports | 2004年 / 6卷 / 6期

关键词：

Thyroid Hormone; Hypothyroidism; Cholesteryl Ester Transfer Protein; Thyroid Dysfunction; Subclinical Hypothyroidism;

D O I：

10.1007/s11886-004-0054-3

中图分类号：

学科分类号：

摘要：

Subclinical and overt hypothyroidism are relatively common disorders in the general population. Thyroid hormone is known to play a role in regulating the synthesis, metabolism, and mobilization of lipids. In patients with overt hypothyroidism there is an increase in serum total cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein B, lipoprotein(a) [Lp(a)] levels, and possibly triglyceride levels. The effects of subclinical hypothyroidism on serum lipid values are less clear. The preponderance of evidence suggests that total cholesterol, LDL cholesterol, and possibly triglycerides are increased in patients with subclinical hypothyroidism, whereas high-density lipoprotein (HDL) cholesterol and Lp(a) remain unchanged. Most lipid abnormalities in patients with overt hypothyroidism will resolve with thyroid hormone replacement therapy. However, clinical trials to date have not shown a beneficial effect of thyroid hormone treatment on serum lipid levels in patients with subclinical hypothyroidism. The lipid-altering effects of thyroid hormone make it an appealing target for drug development. The development of specifically targeted thyroid hormone analogues that could potentially treat hyperlipidemia without causing systemic thyrotoxicosis is currently ongoing. Copyright © 2004 by Current Science Inc.

引用

页码：451 / 456

页数：5

共 49 条

[31]

Hak A.E., Pols H.A.P., Visser T.J., Et al., Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study, Ann. Intern. Med., 132, pp. 270-278, (2000)

[32]

Pazos F., Alvarez J.J., Rubies-Prat J., Et al., Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins, J. Clin. Endocrinol. Metab., 80, pp. 562-566, (1995)

[33]

Milionis H.J., Efstathiadou Z., Tselepis A.D., Et al., Lipoprotein(a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: Effect of treatment with levothyroxine, Thyroid, 13, pp. 365-369, (2003)

[34]

Tan K.C.B., Shiu S.W.M., Kung A.W.C., Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: Roles of hepatic lipase and cholesteryl ester transfer protein, J. Clin. Endocrinol. Metab., 83, pp. 2921-2924, (1998)

[35]

O'Brien T., Katz K., Hodge D., Et al., The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII, and E, Clin. Endocrinol., 46, pp. 17-20, (1997)

[36]

Weintraub M., Grosskopf I., Trostanesky Y., Et al., Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism, J. Clin. Endocrinol. Metab., 84, pp. 2532-2536, (1999)

[37]

Ito M., Takamatsu J., Matsuo T., Et al., Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement, Clin. Endocrinol., 58, pp. 621-626, (2003)

[38]

Sundaram V., Hanna H.F., Koneru L., Et al., Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation, J. Clin. Endocrinol. Metab., 82, pp. 3241-3244, (1997)

[39]

Diekman T., Demacker P.N., Kastelein J.J.P., Et al., Increased oxidizability of low-density lipoproteins in hypothyroidism, J. Clin. Endocrinol. Metab., 83, pp. 1752-1755, (1998)

[40]

Duntas L.H., Mantzou E., Koutras D.A., Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism, Thyroid, 12, pp. 1003-1007, (2002)

← 1 2 3 4 5 →